Chinese company Sinovac defends efficacy of its Covid-19 vaccine
Beijing, Jan 13 (Prensa Latina) The Chinese company Sinovac Biotech ratified the efficacy and safety of its Covid-19 vaccine, after announcing that it will ask the country's regulators to formalize the release on the market.
The president of the pharmaceutical company, Yin Weidong, said that the results of clinical trials in Turkey, Indonesia and now in Brazil, demonstrate the good performance of the medicine - called CoronaVac - in stimulating the immune response.
As he revealed, more than seven million doses have already been applied in China, mainly in Beijing and Guangdong, and the firm is now seeking Hong Kong's approval to supply one million.
According to the official plan, the campaign will then continue free of charge for those with chronic diseases, the rest of the population, and even for native Taiwanese working in mainland China.
Hong Kong also plans to give free and voluntary access to the vaccine, in an effort to stop the spread of the SARS-CoV-2 coronavirus once and for all.
A team from the World Health Organization is currently working with Sinovac and its counterpart Sinopharm, evaluating their vaccines to determine if they meet quality and safety standards before including them on the global list of approved vaccines.
|By the minute||Most read|